Get the free version of Marbridge Daily delivered to your inbox

Click here to subscribe

B2C Pharmaceutical E-tailer 'Jianke' Raises USD 50 Mln Series A+, 5/15/17

Guangdong-based Jianke Pharmaceutical, operator of B2C pharmaceutical e-tailer, has completed USD 50 mln in Series A+ funding, announced Jianke CEO Xie Fangmin. The funding came from investment firms Asia-Pac Ecommerce, Penta Global Advisors Fund, and Huashanshi Investment Management.

The funding will be used for investments in chronic disease management, internet medicine, and exploration of smart healthcare services.

Jianke is planning to launch a number of brick-and-mortar hospitals nationwide, which will serve as a key path towards developing an internet hospital business, revealed Xie. Jianke has completed preparation for an IPO in the United States, and is planning to list on the Nasdaq within the next 2-3 years, according to Xie. However, the company has not eliminated the possibility of listing on a different exchange.

Editor's Note: The company also operates mobile B2C e-commerce app Jianke Doctor (formerly called Palm Doctor), which lets users engage in online consultations with doctors, read health news, perform self-diagnosis based on online descriptions of medical symptoms, and buy drugs through an online pharmacy. also provides similar services to the mobile app. For more information on this topic, please see "B2C Pharmaceutical E-tailer 'Jianke' Lands USD 100 Mln Series A," MD 1/28/16 issue.

Keywords: funding Series A Xie Fangmin Asia-Pac Ecommerce Penta Global Huashanshi VC Internet IPO B2C Jianke e-commerce online healthcare Jianke Doctor mobile healthcare wireless


Please note, all fields are required.
None of your personal information will be shared with third parties.



The information contained in this newsletter is based upon sources that Marbridge Consulting believes to be reliable, and we have made every effort to translate the original articles or article excerpts as faithfully as possible. However, Marbridge Consulting makes no warranty of and assumes no legal responsibility for the accuracy of either the original source material or the English language translations.

Marbridge Daily Premium

Interested in gaining full access to all newsletter articles and the Marbridge Daily archive? To learn more about premium subscription options, including pricing, please:

Click here

Marbridge Consulting RSS Feed

Marbridge Reports